Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate efavirenz across diverse indications, primarily focusing on HIV-1, AIDS, Hepatitis B co-infections, tuberculosis, non-small cell lung cancer, and pharmacokinetic interactions in healthy volunteers and rheumatoid arthritis patients. Supported by academic institutions and government organizations, these investigations encompass completed, actively recruiting, terminated, and withdrawn statuses.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07482085 | RECRUITING | Creutzfeldt-Jakob Disease |
Xuanwu Hospital, Beijing |
2026-04-14 | PHASE3 |
| NCT07631897 | NOT_YET_RECRUITING | HIV; Art Therapy; TB - Tuberculosis |
Shanghai Public Health Clinical Center |
2026-06 | PHASE4 |
| NCT06823596 | RECRUITING | Hiv |
University of Toronto |
2025-01-14 | |
| NCT05789173 | RECRUITING | Drug-Drug Interaction |
Indiana University |
2023-10-06 | EARLY_PHASE1 |
| NCT07341672 | NOT_YET_RECRUITING | Healthy Adult Subject |
Sunshine Lake Pharma Co., Ltd. |
2026-12-31 | PHASE1 |
| NCT05076682 | RECRUITING | Triple-negative Breast Cancer |
Fudan University |
2022-06-30 | PHASE2 |
| NCT07565441 | NOT_YET_RECRUITING | ADPKD (Autosomal Dominant Polycystic Kidney Disease) |
Jemincare |
2026-05-11 | PHASE1 |
| NCT07570069 | COMPLETED | Pain |
Vertex Pharmaceuticals Incorporated |
2026-05-07 | PHASE1 |
| NCT06797674 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2025-02-10 | PHASE1 |
| NCT06914869 | COMPLETED | Healthy Participants |
X4 Pharmaceuticals |
2025-02-18 | PHASE1 |
| NCT04022967 | UNKNOWN | HIV-1-infection |
ANRS, Emerging Infectious Diseases |
2020-09-21 | PHASE3 |
| NCT07193875 | COMPLETED | HIV |
Washington University School of Medicine |
2023-02-09 | PHASE4 |
| NCT06294561 | COMPLETED | Non Small Cell Lung Cancer |
Shenzhen TargetRx Co., Ltd. |
2024-03-04 | PHASE1 |
| NCT04708496 | UNKNOWN | HIV Coinfection; Malaria |
Makerere University |
2021-01-18 | PHASE4 |
| NCT05995249 | COMPLETED | Healthy Volunteers |
Takeda |
2023-08-11 | PHASE1 |
| NCT06698016 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2023-07-25 | PHASE1 |
| NCT04429152 | UNKNOWN | HIV-1-infection |
Professor Francois Venter |
2021-02-09 | PHASE3 |
| NCT05909644 | COMPLETED | Healthy Adult Subjects |
Biogen |
2023-07-05 | PHASE1 |
| NCT05560360 | COMPLETED | B-cell Tumors |
Jiangsu HengRui Medicine Co., Ltd. |
2022-11-04 | PHASE1 |
| NCT05330273 | COMPLETED | Malaria |
Novartis Pharmaceuticals |
2022-04-28 | PHASE1 |
| NCT04513379 | UNKNOWN | HIV Infections; Tuberculosis |
Shanghai Public Health Clinical Center |
2020-11-01 | PHASE3 |
| NCT04504045 | TERMINATED | Diabetes Mellitus, Type 2 |
University of Southern Denmark |
2020-09-01 | PHASE1 |
| NCT04303598 | UNKNOWN | HIV-infection/Aids |
Henan Genuine Biotech Co., Ltd. |
2020-04-01 | PHASE3 |
| NCT05067439 | COMPLETED | Healthy Participants |
Pfizer |
2021-10-21 | PHASE1 |
| NCT03706885 | COMPLETED | Alzheimer Disease, Early Onset |
Case Western Reserve University |
2018-05-05 | PHASE1 |
| NCT05141422 | UNKNOWN | Human Immunodeficiency Virus Infection |
Jiangsu HengRui Medicine Co., Ltd. |
2021-12-13 | PHASE1 |
| NCT04973020 | COMPLETED | Advanced Solid Tumor |
Jiangsu HengRui Medicine Co., Ltd. |
2021-09-01 | PHASE1 |
| NCT01837277 | COMPLETED | Severely Immunocompromised HIV Patients |
Fundação Bahiana de Infectologia |
2017-12-15 | PHASE2; PHASE3 |
| NCT04842981 | Terminated | Arthritis Rheumatoid|Interaction |
University of Southern Denmark|Odense University Hospital|Hospital of South West Jutland|King Christian X´Hospital for Rheumatic Diseases|Sygehus Lillebaelt|Odense Patient Data Explorative Network |
2021-05-25 | Phase 1|Phase 2 |
| NCT03982277 | COMPLETED | Tuberculosis |
Makerere University |
2019-04-30 | PHASE2 |
| NCT04840641 | Completed | Healthy Volunteers|Drug Drug Interaction |
University of Southern Denmark|SignaTope GmbH Germany |
2021-03-25 | Phase 1 |
| NCT04680091 | UNKNOWN | Healthy Subjects, Drug-drug Interaction, Pyrotinib |
Jiangsu HengRui Medicine Co., Ltd. |
2020-11-12 | PHASE1 |
| NCT03282799 | COMPLETED | HIV/AIDS; Contraception |
Catherine Anne Chappell |
2019-02-19 | PHASE2 |
| NCT04463784 | UNKNOWN | HIV/AIDS; Mental Impairment |
Peking Union Medical College Hospital |
2018-04-01 | |
| NCT03819114 | COMPLETED | HIV Infections; Tuberculosis |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2019-05-06 | PHASE2 |
| NCT04424264 | COMPLETED | HIV-1-infection; Tuberculosis |
Professor Francois Venter |
2019-12-05 | PHASE1 |
| NCT04459598 | COMPLETED | Healthy Subjects; Drug-drug Interaction; Pharmacokinetics; Quizartinib |
Daiichi Sankyo Co., Ltd. |
2020-08-19 | PHASE1 |
| NCT03048422 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2018-01-19 | PHASE3 |
| NCT03532425 | TERMINATED | HIV-1-infection |
University of Alberta |
2018-10-29 | PHASE4 |
| NCT03567304 | UNKNOWN | HIV-1-infection; Neurocognitive Dysfunction |
Chiang Mai University |
2018-07-06 | PHASE4 |
| NCT04390334 | COMPLETED | Healthy |
Idorsia Pharmaceuticals Ltd. |
2020-05-13 | PHASE1 |
| NCT03405194 | WITHDRAWN | HIV/AIDS |
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic |
2018-05-01 | |
| NCT03886766 | COMPLETED | Biological Availability; Amorphous Solid Dispersions |
University Hospital, Basel, Switzerland |
2019-04-30 | |
| NCT02722421 | COMPLETED | HIV; Contraception |
University of Nebraska |
2017-04-06 | PHASE2 |
| NCT03983239 | COMPLETED | Healthy Volunteers |
Celgene |
2019-06-21 | PHASE1 |
| NCT03374358 | COMPLETED | HIV Seropositivity; Metabolic Syndrome; Fatty Liver |
Helsinki University Central Hospital |
2018-01-10 | PHASE4 |
| NCT02945163 | COMPLETED | HIV Infections |
Shanghai Public Health Clinical Center |
2018-03-05 | PHASE4 |
| NCT02935075 | COMPLETED | HIV Infections |
Shanghai Public Health Clinical Center |
2018-03-05 | PHASE4 |
| NCT03595709 | COMPLETED | HIV Infections |
Yu-Jay Corp. |
2018-12-06 | PHASE3 |
| NCT03762928 | COMPLETED | Healthy Subjects |
Pfizer |
2018-12-07 | PHASE1 |
| NCT04596488 | COMPLETED | HIV-1-infection |
Peking Union Medical College Hospital |
2017-06-01 | |
| NCT01618305 | COMPLETED | HIV Infections |
Westat |
2013-09-05 | PHASE4 |
| NCT02273765 | COMPLETED | HIV-1 Infection; Tuberculosis |
ANRS, Emerging Infectious Diseases |
2015-09-11 | PHASE3 |
| NCT02652260 | COMPLETED | HIV-1; Central Nervous System |
Merck Sharp & Dohme LLC |
2016-03-04 | PHASE2 |
| NCT02777229 | COMPLETED | HIV-1 Infection |
ANRS, Emerging Infectious Diseases |
2016-07 | PHASE3 |
| NCT03251690 | COMPLETED | Anti-Retroviral Agents; Efavirenz; HIV-1-infection; Sustained Virologic Response; Dyslipidemias; Rilpivirine |
Mahidol University |
2016-10-27 | |
| NCT01980342 | TERMINATED | Drug Interaction |
Johns Hopkins University |
2014-10 | PHASE4 |
| NCT02057796 | COMPLETED | HIV-1 Infection |
ANRS, Emerging Infectious Diseases |
2014-09 | PHASE4 |
| NCT01435018 | COMPLETED | HIV-1 Infection |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2013-10-01 | PHASE3 |
| NCT02832778 | UNKNOWN | HIV |
St Stephens Aids Trust |
2016-11-21 | PHASE1 |
| NCT01986543 | UNKNOWN | Tuberculosis; HIV |
ANRS, Emerging Infectious Diseases |
2013-12 | PHASE2 |
| NCT02178592 | COMPLETED | Infection, Human Immunodeficiency Virus; HIV Infections |
ViiV Healthcare |
2015-01-23 | PHASE3 |
| NCT02631473 | SUSPENDED | HIV |
St Stephens Aids Trust |
2015-11 | PHASE1 |
| NCT02499874 | COMPLETED | HIV |
St Stephens Aids Trust |
2015-08 | PHASE1 |
| NCT02042001 | COMPLETED | Impaired Cognition; Depression/Anxiety; Poor Quality Sleep; Quality of Life; HIV-1 Infection |
Azienda Ospedaliera San Gerardo di Monza |
2015-07-01 | PHASE4 |
| NCT02412436 | COMPLETED | HIV-1 Infection; Tuberculosis |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2015-11-03 | PHASE2 |
| NCT03033368 | UNKNOWN | HIV |
Mahidol University |
2015-07 | PHASE2; PHASE3 |
| NCT02529059 | COMPLETED | HIV |
St Stephens Aids Trust |
2015-11 | PHASE4 |
| NCT02827643 | UNKNOWN | Bone Density |
Mahidol University |
2016-06 | |
| NCT03309566 | COMPLETED | Healthy |
Laboratorio Elea Phoenix S.A. |
2016-09-04 | PHASE4 |
| NCT01900015 | COMPLETED | HCV Coinfection; HIV Infection |
Juan Macías |
2014-02-03 | PHASE4 |
| NCT02447016 | TERMINATED | HIV |
Sheba Medical Center |
2015-05 | PHASE4 |
| NCT02632474 | COMPLETED | HIV Infections |
Shanghai Public Health Clinical Center |
2015-04 | PHASE4 |
| NCT03178084 | COMPLETED | HIV/AIDS |
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
2014-10-15 | PHASE3 |
| NCT02547844 | COMPLETED | HIV-1 |
Hospital Universitari Vall d'Hebron Research Institute |
2015-09 | PHASE4 |
| NCT01978743 | COMPLETED | HIV; HIV-associated Neurocognitive Disorder; Neurotoxicity |
Massachusetts General Hospital |
2014-01 | |
| NCT02345226 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2015-01-26 | PHASE3 |
| NCT01632891 | COMPLETED | HIV-1 Infection; Pf Subclinical Parasitemia |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2014-01-10 | PHASE1; PHASE2 |
| NCT01147107 | COMPLETED | Hepatitis C, Chronic; HIV Infection |
University of Hawaii |
2014-02 | PHASE4 |
| NCT01668147 | COMPLETED | Drug Effects |
Washington University School of Medicine |
2012-08 | PHASE1; PHASE2 |
| NCT02401256 | COMPLETED | Healthy |
Indiana University |
2013-07 | PHASE4 |
| NCT02489461 | COMPLETED | HIV-1-infection |
Viriom |
2014-08-05 | PHASE2; PHASE3 |
| NCT00802802 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2010-02-10 | PHASE1 |
| NCT01352117 | COMPLETED | HIV-1 Infection; Kaposi's Sarcoma |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2011-11-18 | PHASE3 |
| NCT02246998 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2014-12-15 | PHASE4 |
| NCT01989910 | COMPLETED | HIV-1 Infection |
Taipei Veterans General Hospital, Taiwan |
2013-09 | PHASE4 |
| NCT02475915 | COMPLETED | Acute HIV Infection |
SEARCH Research Foundation |
2015-01 | PHASE1; PHASE2 |
| NCT01709084 | COMPLETED | Human Immunodeficiency Virus-type 1 Infection |
Janssen-Cilag International NV |
2013-10-02 | PHASE3 |
| NCT01844297 | UNKNOWN | AIDS/HIV PROBLEM |
Peking Union Medical College |
2013-05 | |
| NCT01929759 | COMPLETED | HIV Disease |
Massachusetts General Hospital |
2014-01 | |
| NCT02164812 | COMPLETED | HIV/AIDS |
Bristol-Myers Squibb |
2014-07 | PHASE1 |
| NCT01935830 | COMPLETED | Healthy Volunteers |
Washington University School of Medicine |
2013-08 | EARLY_PHASE1 |
| NCT00074581 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-02 | PHASE3 |
| NCT02285374 | UNKNOWN | HIV |
St Stephens Aids Trust |
2014-11 | PHASE4 |
| NCT01380080 | COMPLETED | HIV Infection |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2011-10 | PHASE4 |
| NCT01632345 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
2012-10-12 | PHASE2 |
| NCT01146873 | COMPLETED | HIV/AIDS; HIV Infections |
Columbia University |
2010-07 | PHASE3 |
| NCT02670772 | COMPLETED | Acquired Immune Deficiency Syndrome; Human Immunodeficiency Virus |
Willem Daniel Francois Venter |
2012-07 | PHASE3 |
| NCT01778413 | COMPLETED | HIV |
Anna Cruceta |
2013-06-03 | PHASE4 |
| NCT01387022 | COMPLETED | Antiretroviral Treatment Outcomes |
Centre for the AIDS Programme of Research in South Africa |
2011-06 | |
| NCT01878890 | COMPLETED | Solid Tumors; Non-Hodgkin's Lymphoma |
Institut Bergonié |
2011-09-05 | PHASE1 |
| NCT01789879 | COMPLETED | HIV; Contraception |
University of Nebraska |
2014-03-04 | PHASE2 |
| NCT01192035 | COMPLETED | HIV-1 |
University of Aarhus |
2011-05 | PHASE4 |
| NCT01340950 | COMPLETED | HIV Infections; Central Nervous System Diseases; Dementia |
University of California, San Diego |
2010-07 | PHASE4 |
| NCT01515813 | WITHDRAWN | HIV-1 Infection |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2011-11 | PHASE2 |
| NCT01641016 | UNKNOWN | HIV |
PENTA Foundation |
2011-04 | PHASE2; PHASE3 |
| NCT01343225 | UNKNOWN | HIV |
East Carolina University |
2011-05 | PHASE4 |
| NCT01585038 | COMPLETED | Cardiovascular Disease |
Indiana University |
2012-07 | PHASE4 |
| NCT01040091 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2009-12 | PHASE1 |
| NCT02421289 | UNKNOWN | Cytochrome P-450 CYP2B6; Efavirenz; HIV |
Mahidol University |
2013-04 | PHASE1 |
| NCT01690403 | COMPLETED | Tuberculosis |
Sanofi |
2012-12 | PHASE1 |
| NCT01479361 | COMPLETED | HIV; PCP; Toxoplasmosis |
National Institutes of Health Clinical Center (CC) |
2011-10-31 | PHASE1 |
| NCT00978237 | COMPLETED | HIV Infections; Lipoatrophy |
Juan A. Arnaiz |
2009-10 | PHASE4 |
| NCT00924898 | COMPLETED | Acute HIV Infection; HIV Infections |
University of North Carolina, Chapel Hill |
2005-01 | PHASE4 |
| NCT01641809 | COMPLETED | Infection, Human Immunodeficiency Virus; HIV Infections |
ViiV Healthcare |
2012-08-06 | PHASE2 |
| NCT01867996 | COMPLETED | Obstetric Labour, Premature |
GlaxoSmithKline |
2013-06-11 | PHASE1 |
| NCT01516970 | COMPLETED | Human Immunodeficiency Virus (HIV) |
Janssen-Cilag G.m.b.H |
2011-11-25 | PHASE3 |
| NCT01565889 | COMPLETED | Hepatitis C; HIV |
Gilead Sciences |
2012-03 | PHASE1; PHASE2 |
| NCT00946595 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2009-11 | PHASE2; PHASE3 |
| NCT00993031 | COMPLETED | Malaria; HIV Infections |
University of California, San Francisco |
2009-12-15 | PHASE3 |
| NCT00759070 | UNKNOWN | HIV Infections |
Juan A. Arnaiz |
2008-09 | PHASE4 |
| NCT01751555 | COMPLETED | Hiv |
National Center for AIDS/STD Control and Prevention, China CDC |
2011-02 | PHASE4 |
| NCT01704898 | COMPLETED | Healthy |
Center for Clinical Pharmacology Research Bdbeq S.A. |
2013-04 | PHASE4 |
| NCT01293123 | TERMINATED | HIV |
University of California, San Diego |
2011-12 | |
| NCT01195467 | COMPLETED | HIV Infection |
St Stephens Aids Trust |
2010-10 | PHASE3 |
| NCT00984152 | WITHDRAWN | HIV-1 Infections |
Rush University Medical Center |
2011-06 | PHASE3 |
| NCT01011413 | COMPLETED | HIV Infections |
Kirby Institute |
2011-08 | PHASE3 |
| NCT01160120 | COMPLETED | HIV |
The HIV Netherlands Australia Thailand Research Collaboration |
2010-06 | PHASE2 |
| NCT01271894 | COMPLETED | HIV Infection |
Kirby Institute |
2011-09 | PHASE3 |
| NCT01571414 | COMPLETED | Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2012-05 | PHASE1 |
| NCT01254656 | TERMINATED | HIV-1 |
Pfizer |
2011-02 | PHASE2 |
| NCT00878306 | COMPLETED | HIV Infections; Drug Abuse |
University of California, San Francisco |
2008-11 | PHASE1 |
| NCT00870363 | COMPLETED | HIV Infections |
University of California, Davis |
2009-04 | PHASE4 |
| NCT01516060 | COMPLETED | HIV |
Kirby Institute |
2012-01 | PHASE3 |
| NCT01489046 | TERMINATED | HIV-1 Infection |
Bristol-Myers Squibb |
2011-02 | PHASE2 |
| NCT01583439 | TERMINATED | HIV Infections |
Harvard School of Public Health (HSPH) |
2012-09 | |
| NCT01695954 | COMPLETED | Hyperlipidemia; HIV |
NYU Langone Health |
2012-05 | PHASE1 |
| NCT00936195 | WITHDRAWN | HIV Infection; Pregnancy; Breastfeeding; HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2010-01 | PHASE3 |
| NCT00978068 | COMPLETED | Malaria; HIV Infections |
University of California, San Francisco |
2009-09 | PHASE3 |
| NCT00532168 | COMPLETED | HIV Infections |
Juan A. Arnaiz |
2007-09 | PHASE4 |
| NCT00771498 | COMPLETED | HIV Infection; Tuberculosis |
Oswaldo Cruz Foundation |
2008-11 | PHASE4 |
| NCT01805258 | COMPLETED | HIV/TB Co-infection |
All India Institute of Medical Sciences |
2007-06 | PHASE3 |
| NCT01451333 | COMPLETED | HIV Infection |
Kirby Institute |
2011-09 | PHASE3 |
| NCT00533390 | TERMINATED | Tuberculosis; HIV Infections |
Oswaldo Cruz Foundation |
2007-01 | PHASE4 |
| NCT01075152 | COMPLETED | Cryptococcal Meningitis; HIV Infections; AIDS |
University of Minnesota |
2010-11 | PHASE4 |
| NCT01270802 | COMPLETED | HIV |
Indiana University |
2011-04 | PHASE4 |
| NCT01309243 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2011-02 | PHASE3 |
| NCT00102960 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-07 | PHASE3 |
| NCT00734344 | COMPLETED | Acute HIV Infection |
University of Alabama at Birmingham |
2008-09 | |
| NCT01318096 | UNKNOWN | HBV Coinfection; HIV Infections |
Yunnan AIDS Care Center |
2011-03 | |
| NCT01277627 | UNKNOWN | HCV Infection.; HCV Viral Load. |
Valme University Hospital |
2011-01 | |
| NCT01588002 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2012-04 | PHASE1 |
| NCT02404259 | COMPLETED | HIV |
The HIV Netherlands Australia Thailand Research Collaboration |
2010-06 | |
| NCT01190293 | COMPLETED | HIV Infection |
St Stephens Aids Trust |
2010-01 | PHASE4 |
| NCT00545558 | COMPLETED | Hepatitis C; HIV Infections |
University of Cincinnati |
2006-04 | PHASE1 |
| NCT00444379 | COMPLETED | Kaposi's Sarcoma; HIV Infections |
University of California, San Francisco |
2007-04 | PHASE4 |
| NCT00110305 | COMPLETED | Human Immunodeficiency Virus Type 1 |
Tibotec Pharmaceuticals, Ireland |
2005-06 | PHASE2 |
| NCT00364793 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2007-02 | PHASE1; PHASE2 |
| NCT01194856 | TERMINATED | HIV Infection; Mitochondrial Dysfunction |
The Cleveland Clinic |
2010-10 | PHASE4 |
| NCT01472380 | COMPLETED | Healthy |
Mutual Pharmaceutical Company, Inc. |
2011-11 | PHASE1 |
| NCT00822315 | COMPLETED | HIV Infections; Tuberculosis |
ANRS, Emerging Infectious Diseases |
2009-07 | PHASE2 |
| NCT00824421 | COMPLETED | HIV-1 |
Pfizer |
2009-02 | PHASE2 |
| NCT00964002 | COMPLETED | Prostate Cancer |
Institut Bergonié |
2008-05 | PHASE2 |
| NCT00234091 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-04 | PHASE3 |
| NCT01371006 | COMPLETED | Healthy |
Boehringer Ingelheim |
2011-06 | PHASE1 |
| NCT01095796 | COMPLETED | HIV; HIV Infections |
Gilead Sciences |
2010-03 | PHASE3 |
| NCT01231555 | TERMINATED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2010-11-18 | PHASE2 |
| NCT00573001 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2008-07 | PHASE3 |
| NCT00620438 | UNKNOWN | HIV Infections; Tuberculosis |
Makerere University |
2008-02 | PHASE4 |
| NCT01286740 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2011-01 | PHASE2 |
| NCT00752856 | COMPLETED | HIV Infections |
University of California, San Diego |
2008-08-26 | PHASE2 |
| NCT01014481 | TERMINATED | HIV Infections; Tuberculosis |
Bamrasnaradura Infectious Diseases Institute |
2009-10 | PHASE4 |
| NCT01104376 | COMPLETED | Efavirenz, Metabolism and Pharmacokinetics Changes |
Indiana University |
2010-03 | |
| NCT00495326 | COMPLETED | Tuberculosis; Aids; Hiv Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2007-12 | PHASE2; PHASE3 |
| NCT01241773 | COMPLETED | Hepatitis C Virus |
Tibotec Pharmaceuticals, Ireland |
2010-10 | PHASE1 |
| NCT01136928 | COMPLETED | Healthy Volunteers |
Johns Hopkins University |
2010-09-28 | PHASE1 |
| NCT00335322 | COMPLETED | Human Immunodeficiency Virus (HIV) |
Kirby Institute |
2007-02 | PHASE4 |
| NCT01187862 | COMPLETED | Cytochrome; Pharmacokinetics |
University Hospital, Basel, Switzerland |
2010-07 | PHASE1 |
| NCT00992069 | COMPLETED | Tuberculosis; HIV |
National Institute of Allergy and Infectious Diseases (NIAID) |
2009-12 | PHASE1 |
| NCT00525239 | UNKNOWN | HIV Infections |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2004-03 | |
| NCT00775606 | TERMINATED | Acquired Immune Deficiency Syndrome |
Rush University Medical Center |
2008-10 | PHASE4 |
| NCT00615745 | COMPLETED | HIV Infections |
Gilead Sciences |
2008-04 | PHASE4 |
| NCT00266058 | COMPLETED | HIV Infections; Malaria |
University of California, San Francisco |
2005-12 | PHASE1 |
| NCT00640887 | COMPLETED | HIV Infections; Tuberculosis |
French National Agency for Research on AIDS and Viral Hepatitis |
2009-02 | PHASE2 |
| NCT01108926 | COMPLETED | HIV Infection; HIV Infections |
St Stephens Aids Trust |
2010-06 | PHASE1 |
| NCT01601899 | TERMINATED | Mitochondrial Toxicity; Metabolic Complications |
University of Witwatersrand, South Africa |
2008-10 | PHASE4 |
| NCT00661960 | COMPLETED | HIV Infections; AIDS |
University of California, Davis |
2008-03 | |
| NCT01087814 | COMPLETED | HIV; HIV Infections |
University of Minnesota |
2010-02 | PHASE4 |
| NCT00727597 | COMPLETED | Human Immunodeficiency Virus Infections |
Georgetown University |
2008-07 | PHASE3 |
| NCT00765154 | TERMINATED | HIV |
St Stephens Aids Trust |
2008-10 | PHASE4 |
| NCT00964171 | COMPLETED | Pancreatic Cancer |
Institut Bergonié |
2008-08 | PHASE2 |
| NCT00442962 | COMPLETED | HIV Infections |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2007-05 | PHASE4 |
| NCT01098526 | COMPLETED | Infections, Human Immunodeficiency Virus and Herpesviridae |
ViiV Healthcare |
2010-03-16 | PHASE1 |
| NCT00084136 | COMPLETED | HIV Infections |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2005-05 | PHASE4 |
| NCT01268839 | COMPLETED | HIV |
Tibotec, Inc |
2010-01 | PHASE1 |
| NCT00668395 | COMPLETED | HIV |
Indiana University |
2007-05 | |
| NCT00863668 | WITHDRAWN | HIV Infection; HIV Infections |
University of Minnesota |
2009-03 | |
| NCT00951015 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2009-07-30 | PHASE2 |
| NCT00903682 | COMPLETED | HIV Infection; HIV; Acquired Immunodeficiency Syndrome |
Janssen-Cilag International NV |
2009-06 | PHASE2 |
| NCT00862823 | COMPLETED | Healthy |
University of Alabama at Birmingham |
2009-02 | PHASE4 |
| NCT00540449 | COMPLETED | HIV Infections; HIV-1; Human Immunodeficiency Virus Type 1 |
Tibotec Pharmaceuticals, Ireland |
2008-05 | PHASE3 |
| NCT00543725 | COMPLETED | HIV Infections; HIV-1 |
Tibotec Pharmaceuticals, Ireland |
2008-06 | PHASE3 |
| NCT00474435 | UNKNOWN | Tuberculosis; HIV Infections |
African Poverty Related Infection Oriented Research Initiative |
2008-11 | PHASE2 |
| NCT00302822 | COMPLETED | HIV Infections; AIDS |
French National Agency for Research on AIDS and Viral Hepatitis |
2006-04 | PHASE3 |
| NCT01445223 | COMPLETED | HIV |
Göteborg University |
2004-04 | PHASE4 |
| NCT00944957 | UNKNOWN | Sleep Disorders; HIV Infections |
University Hospital, Geneva |
2009-11 | |
| NCT01049685 | UNKNOWN | HIV Infections |
UPECLIN HC FM Botucatu Unesp |
2006-08 | PHASE4 |
| NCT00307502 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2005-01 | PHASE1 |
| NCT00549198 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV Infection |
GlaxoSmithKline |
2007-06 | PHASE4 |
| NCT00414635 | COMPLETED | HIV Infections |
Community Research Initiative of New England |
2006-08 | PHASE4 |
| NCT00869557 | COMPLETED | HIV; HIV Infections |
Gilead Sciences |
2009-04 | PHASE2 |
| NCT00115609 | COMPLETED | HIV Infections; Tuberculosis |
French National Agency for Research on AIDS and Viral Hepatitis |
2006-01 | PHASE3 |
| NCT00118898 | COMPLETED | HIV Infections |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2005-09 | PHASE3 |
| NCT00615810 | COMPLETED | HIV Infections |
Gilead Sciences |
2008-03 | PHASE4 |
| NCT00120510 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2007-07 | |
| NCT00280969 | COMPLETED | HIV Infection |
International Medical Center of Japan |
2005-09 | PHASE3 |
| NCT00792324 | COMPLETED | HIV |
St Stephens Aids Trust |
2008-06 | PHASE3 |
| NCT00810303 | COMPLETED | Pharmacokinetics; Drug Interactions; Pharmacodynamics; Intestinal Transporter Expression |
University Medicine Greifswald |
2009-03 | PHASE1 |
| NCT00100568 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-07 | |
| NCT00332306 | UNKNOWN | Tuberculosis; Human Immunodeficiency Virus Infections |
Tuberculosis Research Centre, India |
2006-06 | PHASE3 |
| NCT00369941 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
2006-08 | PHASE3 |
| NCT00427297 | TERMINATED | HIV Infections |
University of Washington |
2007-09 | PHASE3 |
| NCT00260078 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-02 | PHASE1; PHASE2 |
| NCT00836212 | UNKNOWN | Human Immunodeficiency Virus; HIV Infections |
University Hospital, Geneva |
2008-03 | PHASE4 |
| NCT00828789 | COMPLETED | Hepatitis C; HCV; HIV; AIDS |
Tibotec BVBA |
2009-02 | PHASE1 |
| NCT00016718 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2001-08 | PHASE1; PHASE2 |
| NCT00744809 | COMPLETED | Human Volunteers |
Tibotec Pharmaceuticals, Ireland |
2008-08 | PHASE1 |
| NCT00255840 | COMPLETED | HIV Infections |
CIPRA SA |
2006-07 | |
| NCT00433719 | UNKNOWN | HIV Infections; Tuberculous Meningitis |
University of Oxford |
2005-09 | |
| NCT00483054 | COMPLETED | HIV Infections; Tuberculosis |
Bamrasnaradura Infectious Diseases Institute |
2007-01 | PHASE3 |
| NCT00697892 | COMPLETED | HIV Infections; Malaria |
Fran Aweeka |
2005-07 | PHASE1 |
| NCT00482963 | COMPLETED | HIV Infections; Contraception; Pharmacokinetics |
University of Colorado, Denver |
2007-05 | PHASE1 |
| NCT00966160 | COMPLETED | Acquired Immunodeficiency Syndrome; HIV Infections |
University of Cologne |
1999-01 | PHASE3 |
| NCT00792584 | COMPLETED | Sleep Disorders |
University Hospital, Geneva |
2008-11 | |
| NCT00122538 | COMPLETED | HIV Infections; AIDS |
French National Agency for Research on AIDS and Viral Hepatitis |
2006-02 | PHASE2 |
| NCT00299091 | COMPLETED | HIV |
Germans Trias i Pujol Hospital |
2006-09 | PHASE4 |
| NCT00704249 | COMPLETED | HIV Infections |
Clinical Trial Agency of HIV Study Group |
2006-07 | PHASE4 |
| NCT00476424 | COMPLETED | HIV Infections |
The HIV Netherlands Australia Thailand Research Collaboration |
2007-06 | PHASE2 |
| NCT00342355 | COMPLETED | HIV |
National Institutes of Health Clinical Center (CC) |
2004-01 | PHASE4 |
| NCT00523458 | TERMINATED | HIV Infections; Tuberculosis |
Stanford University |
2007-07 | PHASE4 |
| NCT00162097 | COMPLETED | HIV Infections; Hepatic Impairment |
Bristol-Myers Squibb |
2004-11 | PHASE1 |
| NCT00960570 | COMPLETED | Healthy |
Mutual Pharmaceutical Company, Inc. |
2008-02 | PHASE1 |
| NCT00556634 | COMPLETED | HIV-1 Infection; HIV Infection |
Sociedad Andaluza de Enfermedades Infecciosas |
2006-04 | PHASE4 |
| NCT00457665 | COMPLETED | HIV Infections |
University of Texas Southwestern Medical Center |
2002-02 | PHASE4 |
| NCT00365612 | COMPLETED | HIV Infections |
Gilead Sciences |
2006-07 | PHASE4 |
| NCT00399685 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2006-12 | PHASE1 |
| NCT00350272 | COMPLETED | HIV Infections |
Alexion Pharmaceuticals, Inc. |
2006-05 | PHASE2 |
| NCT00323544 | COMPLETED | HIV Infections |
Gilead Sciences |
2004-10 | PHASE3 |
| NCT00100594 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-05 | |
| NCT00098293 | COMPLETED | HIV-1 |
ViiV Healthcare |
2004-11 | PHASE3 |
| NCT00318123 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2004-04 | PHASE3 |
| NCT00344760 | COMPLETED | HIV Infections |
University of Maryland, Baltimore |
2005-01 | PHASE4 |
| NCT00314626 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2004-11 | PHASE3 |
| NCT00192595 | COMPLETED | HIV Infection; Hepatitis B Coinfection |
Kirby Institute |
2004-01 | PHASE4 |
| NCT00100048 | COMPLETED | HIV Infections; Acquired Immunodeficiency Syndrome |
Merck Sharp & Dohme LLC |
2005-01 | PHASE2 |
| NCT00192660 | COMPLETED | HIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease |
Kirby Institute |
2003-02 | PHASE4 |
| NCT00357188 | COMPLETED | HIV Infections; Protease Inhibitor |
Bristol-Myers Squibb |
2006-07 | PHASE1 |
| NCT02226991 | COMPLETED | Healthy |
Boehringer Ingelheim |
2006-04 | PHASE1 |
| NCT00730223 | COMPLETED | HIV Infections |
Vanderbilt University |
2004-03 | PHASE1 |
| NCT00135343 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2004-04 | PHASE3 |
| NCT00135382 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2002-06 | PHASE3 |
| NCT00135369 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2002-09 | PHASE3 |
| NCT00116116 | COMPLETED | HIV Infections; AIDS |
Bristol-Myers Squibb |
2002-03 | PHASE4 |
| NCT00112047 | COMPLETED | HIV Infections |
Gilead Sciences |
2003-07 | PHASE3 |
| NCT00116298 | COMPLETED | HIV Infections; AIDS |
Bristol-Myers Squibb |
2001-01 | PHASE3 |
| NCT00014937 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00116415 | COMPLETED | HIV Infections; AIDS |
Bristol-Myers Squibb |
2002-03 | |
| NCT00053638 | COMPLETED | HIV Infection |
GlaxoSmithKline |
2003-02 | PHASE3 |
| NCT00028327 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001119 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
1999-10 | |
| NCT00023413 | COMPLETED | HIV Infections; Tuberculosis |
Centers for Disease Control and Prevention |
1999-11 | PHASE2 |
| NCT00001122 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00013897 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2001-02 | PHASE3 |
| NCT00000922 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00543530 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
2001-03 | PHASE3 |
| NCT00005918 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2000-06 | PHASE3 |
| NCT02253823 | COMPLETED | Healthy |
Boehringer Ingelheim |
2001-12 | PHASE1 |
| NCT00021463 | COMPLETED | HIV Infections; Lipodystrophy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00158821 | COMPLETED | HIV Infections |
Gilead Sciences |
2000-03 | PHASE3 |
| NCT00038220 | COMPLETED | HIV Infections |
Abbott |
2000-07 | PHASE2 |
| NCT00000939 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000919 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002448 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
1999-10 | PHASE3 |
| NCT00002230 | COMPLETED | HIV Infections |
Northwestern University |
PHASE3 | |
| NCT00006208 | UNKNOWN | HIV Infections |
Triangle Pharmaceuticals |
2000-08 | PHASE3 |
| NCT00001087 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00075907 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-07 | PHASE3 |
| NCT00256828 | COMPLETED | HIV Infections |
Clinical Trial Agency of HIV Study Group |
2004-06 | PHASE4 |
| NCT00006190 | COMPLETED | HIV Infections; Lipodystrophy |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2000-11 | PHASE4 |
| NCT00001086 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00162643 | UNKNOWN | Acquired Immunodeficiency Syndrome |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2004-12 | PHASE4 |
| NCT00011895 | UNKNOWN | HIV Infections |
GlaxoSmithKline |
2001-02 | PHASE4 |
| NCT00013520 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001818 | COMPLETED | HIV Infection |
National Cancer Institute (NCI) |
1999-06 | PHASE1 |
| NCT00000885 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00016601 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2001-06 | |
| NCT00017758 | COMPLETED | HIV Infections; HIV Seronegativity; Lipodystrophy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00006154 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00005000 | UNKNOWN | HIV Infections |
Agouron Pharmaceuticals |
1999-12 | PHASE4 |
| NCT00100581 | COMPLETED | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00005673 | COMPLETED | Healthy; HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
2000-05 | PHASE1 |
| NCT00197613 | COMPLETED | AIDS; HIV Infection |
Harvard School of Public Health (HSPH) |
2002-12 | PHASE3 |
| NCT00018083 | UNKNOWN | Tuberculosis; HIV Infections |
National Center for Research Resources (NCRR) |
||
| NCT00127959 | COMPLETED | HIV Infections; Hepatitis B |
International Antiviral Therapy Evaluation Center |
2004-03 | PHASE4 |
| NCT00004582 | COMPLETED | HIV Infections |
ViRx |
PHASE2 | |
| NCT00127972 | COMPLETED | HIV Infections |
International Antiviral Therapy Evaluation Center |
2004-02 | PHASE4 |
| NCT00075231 | COMPLETED | HIV Infections |
Abbott |
2003-12 | PHASE2 |
| NCT00029341 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000893 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
1997-10 | PHASE1 |
| NCT00005017 | UNKNOWN | HIV Infections |
Glaxo Wellcome |
PHASE4 | |
| NCT00002447 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
1999-10 | PHASE3 |
| NCT00023218 | WITHDRAWN | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000918 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00121017 | WITHDRAWN | HIV Infection; Hepatitis C |
Abbott |
PHASE2 | |
| NCT00002227 | COMPLETED | HIV Infections |
Dupont Merck |
PHASE2 | |
| NCT00245986 | COMPLETED | Metabolism |
National Institutes of Health Clinical Center (CC) |
2005-10-18 | PHASE4 |
| NCT00196599 | COMPLETED | HIV Infections; Antiretroviral Naive |
ANRS, Emerging Infectious Diseases |
1999-02 | PHASE2 |
| NCT00002362 | SUSPENDED | HIV Infections |
Triangle Pharmaceuticals |
1999-08 | PHASE3 |
| NCT00001758 | COMPLETED | HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
1997-11 | PHASE2 |
| NCT00002225 | COMPLETED | HIV Infections |
Dupont Merck |
PHASE2 | |
| NCT00158405 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2002-12 | PHASE3 |
| NCT00000903 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00091936 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2009-08 | |
| NCT00031070 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001766 | COMPLETED | HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
1998-08 | PHASE1 |
| NCT00002239 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
1999-05 | PHASE2 |
| NCT00002387 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
||
| NCT00038532 | COMPLETED | HIV Infections |
Abbott |
2001-04 | PHASE2 |
| NCT00005762 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2001-03 | |
| NCT00080522 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-02 | |
| NCT00386659 | TERMINATED | HIV Infection |
Hospital Clinic of Barcelona |
PHASE4 | |
| NCT00158470 | COMPLETED | HIV Infection |
French National Agency for Research on AIDS and Viral Hepatitis |
2003-09 | PHASE3 |
| NCT00044837 | TERMINATED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00531323 | COMPLETED | HIV Infections |
St Stephens Aids Trust |
2007-09 | PHASE1 |
| NCT00050895 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00005018 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-07 | PHASE4 |
| NCT00051090 | WITHDRAWN | HIV Infections; Hepatitis B |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002220 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE3 | |
| NCT00214435 | UNKNOWN | HIV Infection; AIDS |
407 Doctors |
2004-05 | PHASE4 |
| NCT00002393 | COMPLETED | HIV Infections |
Dupont Merck |
PHASE3 | |
| NCT00000914 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00004585 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-10 | PHASE4 |
| NCT00004852 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-09 | PHASE2 |
| NCT00224458 | COMPLETED | HIV Infections |
Gilead Sciences |
2004-09 | PHASE4 |
| NCT00158457 | COMPLETED | HIV Infection |
French National Agency for Research on AIDS and Viral Hepatitis |
2004-06 | PHASE3 |
| NCT00000912 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002234 | COMPLETED | HIV Infections |
Gilead Sciences |
PHASE2 | |
| NCT00002419 | COMPLETED | HIV Infections |
Gilead Sciences |
PHASE2 | |
| NCT00002213 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE2 | |
| NCT00405171 | COMPLETED | HIV Infections; Hypercholesterolemia; Antiretroviral Therapy |
University Hospital, Caen |
2003-06 | PHASE4 |
| NCT00196612 | COMPLETED | HIV Infections |
ANRS, Emerging Infectious Diseases |
2001-04 | PHASE3 |
| NCT00002235 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Check the
Efavirenz
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.